INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 290 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $792,654 | -17.7% | 15,217 | 0.0% | 2.55% | -16.4% |
| Q2 2023 | $963,540 | +10.3% | 15,217 | -5.7% | 3.05% | +25.7% |
| Q1 2023 | $873,548 | -11.2% | 16,132 | -13.2% | 2.42% | -24.7% |
| Q4 2022 | $983,889 | -21.1% | 18,592 | -30.6% | 3.22% | -25.0% |
| Q3 2022 | $1,247,000 | -42.0% | 26,792 | -28.9% | 4.29% | -53.6% |
| Q2 2022 | $2,151,000 | -22.8% | 37,692 | -17.2% | 9.25% | +43.7% |
| Q1 2022 | $2,786,000 | -25.8% | 45,533 | -36.5% | 6.44% | +112.7% |
| Q4 2021 | $3,755,000 | – | 71,742 | – | 3.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |